Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801) |
|
|
|
Vollpublikation |
2018 |
Ösophagus-/Magenkarzinome
|
|
|
www.sciencedirect.com/science/article/pii/S0959804918301138 |
|
|
A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor- NIVOSWITCH (AIO-NZK-0116) |
|
|
|
Abstract |
2018 |
Nierenzellkarzinom
|
|
|
|
|
|
A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor- NIVOSWITCH (AIO-NZK-0116) |
|
|
|
Poster |
2018 |
Nierenzellkarzinom
|
|
|
|
|
|
PREPARE: A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib (AIO-NZK-0115/ass) |
|
|
|
Poster |
2018 |
Nierenzellkarzinom
|
|
|
|
|
|
Vinorelbin plus Everolimus versus Vinorelbin Monotherapy als Zweitlinientherapie des HER2 negativen fortgeschrittenen Mammakarzinoms. Finale Ergebnisse der randomisierten Phase II Studie VicTORia / Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial VicTORia |
|
|
|
Abstract |
2018 |
Mammakarzinom / gynäkologische Tumoren
|
|
|
|
|
|
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial |
|
|
|
Vollpublikation |
2018 |
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
epub.ub.uni-muenchen.de/59228/index.html |
|
|
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial |
|
|
|
Vollpublikation |
2018 |
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
www.sciencedirect.com/science/article/pii/S0959804918309092 |
|
|
mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109) |
|
|
|
Abstract |
2018 |
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3509 |
|
|
Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial |
|
|
|
Abstract |
2018 |
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e15599 |
|
|
Großangelegtes Registerprojekt CRISP – Dokumentation eines rasanten Therapiewandels |
|
|
|
Sonstige |
2017 |
Thorakale Onkologie
|
|
|
www.springermedizin.de/grossangelegtes-registerprojekt-crisp-dokumentation-eines-rasant/12113942 |
|
|